MBX Biosciences, Inc./$MBX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Ticker
$MBX
Sector
Primary listing
Employees
43
Headquarters
Website
MBX Metrics
BasicAdvanced
$727M
-
-$2.88
-
-
Price and volume
Market cap
$727M
52-week high
$26.47
52-week low
$4.81
Average daily volume
1.8M
Financial strength
Current ratio
19.496
Quick ratio
19.203
Long term debt to equity
0.234
Total debt to equity
0.296
Profitability
EBITDA (TTM)
-86.285
Management effectiveness
Return on assets (TTM)
-36.75%
Return on equity (TTM)
-56.28%
Valuation
Price to book
2.49
Price to tangible book (TTM)
2.49
Price to free cash flow (TTM)
-6.065
Free cash flow yield (TTM)
-16.49%
Free cash flow per share (TTM)
-2.681
Growth
Earnings per share change (TTM)
-92.85%
Bulls say / Bears say
MBX ended Q2 2025 with $224.9 million in cash, cash equivalents and marketable securities, providing a runway into mid-2027 and reducing near-term financing risk. (GLOBE NEWSWIRE)
Once-weekly canvuparatide met its primary composite endpoint in the Phase 2 Avail trial, achieving a 63% responder rate at 12 weeks and 79% at 6 months with a favorable safety profile, de-risking its Phase 3 initiation. (MBX Biosciences)
MBX submitted an IND for MBX 4291 on June 16, 2025 and remains on track to initiate its Phase 1 trial in Q3 2025, broadening its pipeline into the high-potential obesity market. (GLOBE NEWSWIRE)
With no approved products, MBX’s valuation hinges on upcoming binary clinical readouts for canvuparatide topline data in Q3 2025 and first-in-human results for MBX 4291 in 2027. (GLOBE NEWSWIRE)
MBX’s cash position declined by ~$37.2 million from $262.1 million at year-end 2024 to $224.9 million at June 30, 2025, indicating a high burn rate that could pressure financing if milestones slip. (GLOBE NEWSWIRE)(GLOBE NEWSWIRE)
MBX 4291 faces an obesity market dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro/Zepbound, which hold the majority GLP-1 share and leverage extensive R&D and commercial infrastructure. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MBX Biosciences, Inc. stock?
MBX Biosciences, Inc. (MBX) has a market cap of $727M as of October 07, 2025.
What is the P/E ratio for MBX Biosciences, Inc. stock?
The price to earnings (P/E) ratio for MBX Biosciences, Inc. (MBX) stock is 0 as of October 07, 2025.
Does MBX Biosciences, Inc. stock pay dividends?
No, MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next MBX Biosciences, Inc. dividend payment date?
MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders.
What is the beta indicator for MBX Biosciences, Inc.?
MBX Biosciences, Inc. (MBX) does not currently have a Beta indicator.